Successful Treatment of Neuromyelitis Optica with Rituximab
Hyun Du Noh, MD, Min Su Park, MD
Department of Neurology, Yeungnam University College of Medicine, Daegu, Korea
Neuromyelitis optica (NMO) is an idiopathic inflammatory disorder of the central nervous system.
Clinical, laboratory, and immunologic features suggest that NMO is a humorally mediated disease and B cell targeted therapy is ideal and effective treatment in NMO. We describe a 35-year-old woman with NMO, who suffered from very frequent attacks despite the maintenance of long-term prednisolone therapy, dramatically responded to rituximab.
Journal of Multiple Sclerosis 1(2):59-63, 2010
